MedPath

First-in-man Safety and Efficacy Trial of a Novel Non-invasive Bladder Emptying Device: The NIBED Study

Not Applicable
Terminated
Conditions
Urinary Retention
Interventions
Device: Non-invasive bladder emptying device
Registration Number
NCT04919798
Lead Sponsor
Insel Gruppe AG, University Hospital Bern
Brief Summary

The non-invasive bladder emptying device (NIBED) is a handheld medical device that is applied to the penis during urinating to aid bladder emptying in urinary retention patients with increased residual urine volume.

This pilot study primarily seeks to determine the safety of the NIBED. Secondary objectives are to assess the efficacy of the NIBED, which is defined as the ability of the medical device to aid or improve bladder emptying, i.e. leads to less residual urine compared to not using the NIBED.

During the intervention, the study participant will urinate with and without the NIBED. Safety variables such as penile pain, penile lesions and hematuria will be recorded. Efficacy will be assessed by measuring voided volume, residual volume, voiding time and urine flow rate.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
Male
Target Recruitment
10
Inclusion Criteria
  • Informed Consent as documented by signature
  • Age 18 years or older
  • Sex: male
  • Diagnosed with underactive bladder (UAB) (confirmed with urodynamic testing)
Exclusion Criteria
  • Acute urinary tract infection
  • Patients on anti-coagulants (exception Aspirin)
  • Penile pain (NPRS score >2)
  • Pain during voiding (NPRS >2)
  • Penile lesions (NRS score >2)
  • Hematuria >2+
  • Mechanical subvesical obstruction (confirmed by cystoscopy) (exception BPO)
  • Transurethral resection of the prostate (TURP) less than three months before visit 2
  • Penile abnormalities (Buried penis, Peyronie's disease, skin lesions)
  • Asensitive bladder (no sensation of bladder fullness)
  • Shy bladder
  • Indwelling transurethral catheter
  • Inability to understand and follow the study protocol
  • Previous enrolment into the current study
  • Enrolment of the investigator, his/her family members, employees and other dependent persons
  • Participation in another interventional clinical trial within 3 months prior to visit 2 or planned participation during the trial
  • Lacking capacity for consent

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Urinating with NIBED first, without NIBED secondNon-invasive bladder emptying deviceUrinating with NIBED first, without NIBED second
Urinating without NIBED first, with NIBED secondNon-invasive bladder emptying deviceUrinating without NIBED first, with NIBED second
Primary Outcome Measures
NameTimeMethod
Number of patients with adverse events of special interest (AESI)7 days

Number of patients with adverse events of special interest (AESI)

Penile pain7 days

Assessment of penile pain (reported as numeric pain rating scale (NPRS): 0 (no pain at all) to 10 (worst imaginable pain))

Hematuria7 days

Assessment of hematuria (dipstick urinalysis, scale: negative, 1+, 2+, 3+, 4+, macrohematuria (visible))

Penile lesions7 days

Assessment of penile lesions (visually assessed and reported as numeric rating scale (NRS): 0 (none) to 5 (exposed urethra))

Secondary Outcome Measures
NameTimeMethod
Voided urine volume1 day

Assessment of voided urine volume, measured by uroflowmeter/scale \[ml\]

Voiding time1 day

Assessment of voiding time, measured with clock \[s\]

Residual volume1 day

Assessment of residual volume, measured with ultrasound bladder scanner \[ml\]

Urine flow rate1 day

Assessment of urine flow rate, measured with uroflowmeter \[ml/s\]

Trial Locations

Locations (1)

Bern University Hospital Inselspital

🇨🇭

Bern, Switzerland

© Copyright 2025. All Rights Reserved by MedPath